GenVec Inc.

Douglas J. Swirsky joined GenVec in 2006 and serves as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary. Prior to joining GenVec, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus and held the same position at Legg Mason prior to Stifel Financial's acquisition of the Legg Mason Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and a CFA charterholder, has also previously held investment banking positions at UBS, PaineWebber and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his B.S. in Business in Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University.

Bryan T. Butman, Ph.D. joined the company in September, 1999 and now serves as Senior Vice President of Vector Operations. Dr. Butman previously served as GenVec's Vice President of Vector Operations (2005 to 2006), Vice President of Quality (2002 to 2005), and Director of Quality and Analytical Science (1999 to 2002). Prior to joining GenVec, Dr. Butman was Executive Director of Diagnostic Product Research and Development with INTRACEL Corporation, a biotechnology company. Dr. Butman has over 23 years of biotechnology product development experience including clinical gene therapy, human monoclonal antibody and clinical diagnostic products. Throughout his biotechnology career, Dr. Butman has developed successful products in the areas of oncology, cardiovascular disease, infectious disease, food safety and hematology. He has held senior positions within Warner Lambert, AKZO-Nobel, Organon Teknika, PerImmune and INTRACEL. Dr. Butman holds a Ph.D. in Cell Biology from Wayne State University.

C. Richter King, Ph.D. serves as Senior Vice President of Research, and previously as Vice President of New Product Research, an area that he still oversees. Prior to joining GenVec in 1998, Dr. King conducted extensive research into the amplification of the erbB-2 gene, which is associated with common human cancers. Dr. King directed an experienced research group at the Georgetown University Medical School’s Lombardi Cancer Research Center in Washington, DC, where he served as Associate Professor with the University’s Department of Biochemistry. Previously, Dr. King was the Director of Drug Discovery for Oncologix (now Antigenics, Inc.). Dr. King holds a Ph.D. in Biochemistry from Johns Hopkins University.

Mark O. Thornton, M.D., M.P.H., Ph.D. serves as Senior Vice President of Product Development. Dr. Thornton, a Clinical Pharmacologist and Trialist, has divided his 15-year career at FDA and in the biotechnology industry equally between oncology and infectious disease biologics clinical development. At the FDA, he was on the clinical review team for Erbitux(R) for its initial colon cancer indication, and Pegasys(R) for its Hepatitis C indication. At the FDA he also led the initial efforts to establish the FDA Gene Therapy Patient Tracking System and published on the topic of optimizing regulatory pathways for cancer vaccines. In industry, Dr. Thornton has performed Phase I-III clinical trials in both oncology and infectious disease settings, and successfully submitted PLAs for Certiva(TM) while at North American Vaccine and WinRho(R) while at Univax Biologics.

Milan Kovacevic, M.D., Ph.D. joined GenVec in 2006 and serves as Vice President of Clinical Operations. Dr. Kovacevic brings to GenVec extensive and diverse clinical research experience in the pharmaceutical/biotechnology industry. Prior to GenVec, he served as Senior Medical Director/Medical Director at Alteon, Inc., a biopharmaceutical company. Previous experience includes service as Medical Officer for global safety and Project Manager at Kendle International, a clinical development organization, and Clinical Research Scientist at biotechnology company Cangene Corporation. Dr. Kovacevic obtained his medical degree, Master of Science degree in gastroenterology, and doctoral degree in nephrology at the University of Beograd in Yugoslavia. Prior to entering the pharmaceutical industry, Dr. Kovacevic practiced medicine for ten years.

Dr. Kessler is Senior Vice President, Clinical, Medical and Regulatory Affairs as of March 2007. Joining Nabi Biopharmaceuticals in 2005, he most recently served as Vice President, Clinical Research. He spent over 6 years at GenVec, Inc., a gene therapy company, as Head of Clinical Research where he led clinical efforts in therapeutic angiogenesis, oncology and anti-angiogenesis (macular degeneration). From 1989 to 1998, he was an Assistant Professor and later Associate Professor of Medicine at the Johns Hopkins University School of Medicine, where he conducted gene and cell therapy research; and he was an attending cardiologist on the Heart Failure and Transplant Service. He earned a B.S. from the University of Pittsburgh, a M.Sc. from the University of London, and an M.D. from Columbia University College of Physicians and Surgeons. He trained in internal medicine and was a research fellow in heart failure at The Mount Sinai Hospital, New York, and was a research and clinical fellow in Cardiology at the Johns Hopkins University, where he was a National Institutes of Heath Physician Scientist Award recipient. He is the author of 45 peer reviewed research articles and has received 5 issued U.S. patents.

Stelios Papadopoulos, Ph.D. is a co-founder of Anadys and has served as a member of our board of directors since May 2000. His career in biotech spans more than two decades. In August 2006 he resigned as Vice Chairman of Cowen & Co., LLC where he had been an investment banker focused on the biotechnology and pharmaceutical sectors since 2000. Dr. Papadopoulos was an investment banker at PaineWebber Incorporated from 1987 to 2000, most recently serving as Chairman of Paine Webber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Prior to joining PaineWebber in 1987 he was a Vice President in the Equity Research Department of Drexel Burnham Lambert covering the biotechnology industry and a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University. He is co-founder and Chairman of the Board of Exelixis, Inc., co-founder and member of the Board of Cellzome Inc., as well as a member of the Board of Directors of Biogen Idec and BG Medicine, Inc. In the not-for-profit sector, he is co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke University Medical Center.

Mr. Reinhart joined Millennium in October, 2007 with over 25 years of diverse financial experience, including 15 years within the biopharmaceutical industry. At Millennium, Mr. Reinhart leads the finance team, overseeing the accounting and financial reporting, financial planning and analysis, tax, treasury, insurance and strategic sourcing functions and leads/participate in all capital market and business development transactions. Prior to joining Millennium, Mr. Reinhart fulfilled similar responsibilities as the Vice President, Finance at Cephalon, Inc. from 2000 to 2007. During his tenure at Cephalon, the company grew into a profitable, top tier biotechnology company with 3000 employees and annual revenues of approximately $2 billion. From 1990 to 2000, Mr. Reinhart held executive positions in finance at several early stage healthcare and biotechnology companies including Delsys Pharmaceutical Corporation, GenVec, Inc. and Dynamic Digital Displays, Inc. From 1982 to 1986, Mr. Reinhart was employed by the public accounting firm of Ernst & Whinney (now Ernst & Young), rising to the level of Audit Manager. Mr. Reinhart is a certified public accountant. He graduated cum laude from Lehigh University with a Bachelor of Science degree in Accounting and earned an M.B.A. from The Wharton School, University of Pennsylvania.

Dr. Lee R. Wrubel, General Partner, Foundation Medical Partners, has over ten years of experience in venture capital and has been associated with a large number of private companies, including such now publicly traded companies as Pozen Pharmaceuticals, OraPharma, and GenVec. Prior to starting Foundation Medical Partners, Dr. Wrubel was an investment professional with Canaan Partners and more recently Highland Capital Partners, where he specialized in biotechnology and medical device investments. Dr. Wrubel serves on the board of directors of EndoGastric Solutions, Inc., CardioMEMS, Inc. and Vascular Architects, Inc. Dr. Wrubel began his business career as a consultant at The Wilkerson Group, a health care-focused management consulting company. Dr. Wrubel completed a pediatric internship at Mount Sinai Medical Center in New York. He holds an A.B. from Lafayette College, an M.D. and Masters in Public Health from Tufts University, and an M.B.A. from Columbia University. Dr. Wrubel serves on the Translational Research Advisory Committee of the Muscular Dystrophy Association, and is a member of the Health Leadership Council of Save The Children.

C. Richter King, Ph.D. serves as Senior Vice President of Research, and previously as Vice President of New Product Research, an area that he still oversees. Prior to joining GenVec in 1998, Dr. King conducted extensive research into the amplification of the erbB-2 gene, which is associated with common human cancers. Dr. King directed an experienced research group at the Georgetown University Medical School's Lombardi Cancer Research Center in Washington, DC, where he served as Associate Professor with the University's Department of Biochemistry. Previously, Dr. King was the Director of Drug Discovery for Oncologix (now Antigenics, Inc.). Dr. King holds a Ph.D. in Biochemistry from Johns Hopkins University.

Barbara Hackman Franklin is President and Chief Executive Officer of Barbara Franklin Enterprises, a private investment and consulting firm headquartered in Washington, DC. She is a respected counselor and advocate for American companies doing business in international markets, notably China, and a leading expert on corporate governance, auditing, and financial reporting practices. As the 29th U.S. Secretary of Commerce in the administration of President George H.W. Bush, she achieved a major goal increasing American exports with emphasis on market-opening initiatives in China, Russia, Japan and Mexico. Her historic mission to China in 1992 normalized commercial relations with that country and removed one of the sanctions the ban on ministerial contact that the U.S. had imposed following the events at Tiananmen Square in 1989. Franklin has been a director of fourteen public companies and is currently a director of four Aetna Inc., The Dow Chemical Company, MedImmune, Inc., and GenVec, Inc., as well as the Washington Mutual Investors Fund. She currently chairs the audit committees at Dow, GenVec, and MedImmune and the Nominating & Governance Committee at Aetna. For her outstanding contributions to audit excellence, she received the prestigious John J. McCloy award in 1992. She has been recognized as a Director of the Year by The National Association of Corporate Directors (2000) and an Outstanding Director by the Outstanding Director Exchange (2003). She is a regular commentator on corporate governance and international economic matters on the PBS Nightly Business Report. Franklin is Chairman of the Economic Club of New York, vice chairman of the US-China Business Council, and a member of the Board of Directors of the National Association of Corporate Directors and the Public Company Accounting Oversight Board Advisory Council. She is chair of the Asian Studies Center Advisory Council of the Heritage Foundation and a member of numerous other international organizations, including the Council on Foreign Relations, the Atlantic Council, the Woodrow Wilson Center for Scholars Advisory Council, and the Japan Society. Prior to her service as Secretary of Commerce, Franklin's trailblazing career included corporate, governmental, academic, and entrepreneurial activities. In 1984, she founded Franklin Associates, a management consulting firm, and served as its president until 1992. She was also a Senior Fellow at the Wharton School of Business and Director of the Wharton Government and Business Program through the 1980s. Franklin served as one of the original commissioners of the US Consumer Product Safety Commission from 1973-79. She led the first White House effort to recruit women for high-level government jobs as a staff assistant to President Nixon, an effort which resulted in tripling the number of women in those positions during her tenure (1971-73). Earlier, Franklin was assistant vice president at Citibank and manager of environmental analysis at the Singer Company. She served four terms on the Advisory Committee for Trade Policy and Negotiations, by appointments of Presidents Reagan and Bush. Altogether, Franklin has served five U.S. Presidents. Born in Lancaster County, Pennsylvania, Franklin graduated with distinction from the Pennsylvania State University. She was one of the first women graduates of the Harvard Business School from which she has received an Alumni Achievement Award. She has received numerous honorary degrees, honors, and awards and is a frequent speaker, author, and commentator.

Herbert Conrad is currently Chief Executive Officer of Sapphire Therapeutics. Mr. Conrad was US president of Roche Pharmaceuticals a company he was affiliated with for 33 years. He has served on the Boards of Dura, UroCor, Sicor, GenVec, and Bone Care International. Mr. Conrad is currently on the Boards of Savient Pharmaceuticals, Celldex Therapeutics, and Symphony Evolution. Mr. Conrad earned his undergraduate and graduate degrees in Pharmacy from the Brooklyn College of Pharmacy. He also has received a Doctorate in Humane Letters (Honorary) from Long Island University.

Kevin M. Rooney joined the GenVec Board in January 2008. He is a member of the Audit Committee. Mr. Rooney is currently the President of Beacon Consulting Group, a company focused on providing strategic consulting services to biopharmaceutical executives. Previously, he served as Vice President, Sales and Marketing for MedImmune's oncology division, as well as Senior Director of Marketing for Synagis® (palivizumab), MedImmune’s $1.2B monoclonal antibody for the prevention of respiratory infections in preterm infants. Prior to joining MedImmune in July 2003, Mr. Rooney worked for Bristol-Myers Squibb Company, where he held positions of increasing responsibility in sales and marketing management. Mr. Rooney also held marketing positions at GlaxoWellcome, Inc. and Burroughs Wellcome Company, as well as a sales position at The Upjohn Company. He received his Master's degree in management from the J.L. Kellogg Graduate School of Management at Northwestern University and his Bachelor's degree from the University of Virginia.